In the present study, FMT and SCFA treatment reversed CCH-induced alterations to the proportions of CD4+IL-10+ and FOXP3+IL-10+ cells, suggesting that IL-10 might play an important role in alleviating colonic inflammation in response to CCH and, thus, presents a potential therapeutic target. The gene discussed is IL10; the disease is columnar cell hyperplasia of the breast.